J&J names new PR chief as consumer pharma head retires

Share this article:
Johnson & Johnson is promoting the head of its global vision care business to serve as its marketing and PR chief, replacing global OTC chairman Brian Perkins, who is retiring, in that role.

Michael Sneed is moving up to VP, global corporate affairs, in which role he will preside over the marketing giant's corporate affairs team, currently led by Perkins, and public affairs/corporate communication department, led by Ray Jordan, reporting directly to chairman and CEO Bill Weldon. Sneed, currently company group chairman with primary responsibility for J&J's global vision care franchise, joined the company in 1983 as a marketing assistant for Personal Products Company, working his way up through a variety of global marketing roles and leading the McNeil Nutritionals Worldwide and Personal Products Company units.

Perkins has served as corporate VP for the past seven years and worldwide chairman, consumer pharmaceuticals and nutritionals for the past 13 years. The 57-year-old's retirement comes as J&J struggles to win back trust after a series of product safety scandals involving shoddy manufacturing practices, mostly in its OTC division. The moves were first reported in Advertising Age, which speculated that Perkins' advertising responsibilities could go to other execs while Sneed takes charge of communications.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...